A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs BNZ 1 (Primary)
- Indications Alopecia areata; T-cell leukaemia; Tropical spastic paraparesis
- Focus Adverse reactions
- Sponsors Bioniz
- 12 May 2018 Status changed from active, no longer recruiting to completed.
- 01 May 2018 According to a Bioniz media release, full results will be at the 2018 International Investigative Dermatology Meeting.
- 01 May 2018 Results presented in a Bioniz Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History